glp 1 clinical trials Market Overview: GLP-1 Agonists and the Obesity Market | Blog Obesity Clinical Trials | Expert

Clin Pharmacokinet 1985, 10: 155-163

Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]

Clin Endocrinol (Oxf) (1986) 25:13342

Journal of strength and conditioning research , 22 (4), 11301135

The difference is mental load

It is mainly present in muscle tissue and in the heart, as well as in nerve tissue